{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:33:15Z","timestamp":1781818395497,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK","award":["GSK"],"award-info":[{"award-number":["GSK"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Interpretation thresholds for patient-reported outcome (PRO) scores are of crucial importance, particularly when interpreting treatment benefit. This study was designed to determine the within-patient meaningful improvement (WPMI) thresholds for the Short-Form 36 Health Survey version 2 (SF-36v2), the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), and the novel Rheumatoid Arthritis Symptoms and Impact Questionnaire (RASIQ) among patients with rheumatoid arthritis (RA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this <jats:italic>post-hoc<\/jats:italic> analysis, anchor-based and supportive distribution-based methods were used to derive WPMI based on blinded data from all treatment arms in two Phase 2 RA trials with otilimab. Patient\u2019s Global Assessment of Disease Activity (PtGA) was the general anchor for all SF-36v2 scales. SF-36 Patient\u2019s Global Impression of Status (PGIS), PtGA, and VT03 (an SF-36v2 item) were used as anchors for FACIT-Fatigue. SF-36 PGIS, PtGA, and Patient\u2019s Assessment of Arthritis Pain (PAIN) were anchors for RASIQ. Mean change was calculated for the anchor category associated with minimal meaningful improvement from baseline to Week 24 for SF-36v2 and FACIT-Fatigue, and to Week 12 for RASIQ. Sensitivity and specificity were used to evaluate the accuracy of estimated WPMI values.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For the SF-36v2 physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health domains, anchor-based estimates of WPMI based on 0\u2013100 scores were 24.5, 24.5, 25.4, 13.6, 21.5, 20.5, 16.9, and 14.3, respectively. Anchor-based WPMI estimates were 9.7 for the Physical Component Summary score and 7.6 for the Mental Component Summary score (using norm-based T-score metric). For FACIT-Fatigue (range 0\u201352), WPMI estimates ranged from 9.7 to 11.3 points. For RASIQ (range 0\u2013100), anchor-based WPMI was determined as a change between -32.7 and -21.7 points for the Joint Pain scale, -26.7 to -23.7 for the Joint Stiffness scale, and -21.1 to -17.4 for the Impact scale.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study derived WPMI thresholds for SF-36v2, FACIT-Fatigue, and RASIQ among patients with RA, using multiple anchors. Derivation of WPMI thresholds for these PRO instruments will enable their broader use in evaluating and interpreting treatment benefit in future RA studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00685-0","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T14:02:47Z","timestamp":1705932167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Meaningful score changes for SF-36v2, FACIT-fatigue, and RASIQ in rheumatoid arthritis"],"prefix":"10.1186","volume":"8","author":[{"given":"Regina","family":"Rendas-Baum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kosinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Bue","family":"Bjorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite G.","family":"Bracher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"issue":"5","key":"685_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/s0895-4356(03)00044-1","volume":"56","author":"RD Crosby","year":"2003","unstructured":"Crosby RD, Kolotkin RL, Williams GR (2003) Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 56(5):395\u2013407. https:\/\/doi.org\/10.1016\/s0895-4356(03)00044-1","journal-title":"J Clin Epidemiol"},{"key":"685_CR2","doi-asserted-by":"publisher","first-page":"205566831989277","DOI":"10.1177\/2055668319892778","volume":"7","author":"B Byrom","year":"2020","unstructured":"Byrom B, Breedon P, Tulkki-Wilke R, Platko JV (2020) Meaningful change: defining the interpretability of changes in endpoints derived from interactive and mHealth technologies in healthcare and clinical research. J Rehabil Assist Technol Eng 7:2055668319892778. https:\/\/doi.org\/10.1177\/2055668319892778","journal-title":"J Rehabil Assist Technol Eng"},{"key":"685_CR3","unstructured":"US Food and Drug Administration (2019) Incorporating clinical outcome assessments into endpoints for regulatory decision-making. Available via https:\/\/www.fda.gov\/media\/132505\/download. Accessed 19 April 2023"},{"issue":"2","key":"685_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/ard.2007.084848","volume":"68","author":"U Kalyoncu","year":"2008","unstructured":"Kalyoncu U, Dougados M, Daur\u00e8s JP, Gossec L (2008) Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 68(2):183\u2013190. https:\/\/doi.org\/10.1136\/ard.2007.084848","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"685_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s41687-021-00400-3","volume":"5","author":"B Becker","year":"2021","unstructured":"Becker B, Bracher M, Chauhan D, Rendas-Baum R, Lin X, Raymond K, O\u2019Connor M, Kosinski M (2021) Development, psychometric evaluation and cognitive debriefing of the rheumatoid arthritis symptom and impact questionnaire (RASIQ). J Patient Rep Outcomes 5(1):129. https:\/\/doi.org\/10.1186\/s41687-021-00400-3","journal-title":"J Patient Rep Outcomes"},{"issue":"11","key":"685_CR6","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/S2665-9913(20)30229-0","volume":"2","author":"CD Buckley","year":"2020","unstructured":"Buckley CD, Sim\u00f3n-Campos JA, Zhdan V, Becker B, Davy K, Fisheleva E, Gupta A, Hawkes C, Inman D, Layton M, Mitchell N, Patel J, Saurigny D, Williamson R, Tak PP (2020) Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study. Lancet Rheumatol 2(11):e677\u2013e688. https:\/\/doi.org\/10.1016\/S2665-9913(20)30229-0","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"685_CR7","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1016\/S2665-9913(20)30224-1","volume":"2","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Berkowitz M, Conaghan PG, Peterfy C, Davy K, Fisheleva E, Gupta A, Inman D, Janiczek R, Layton M, Mitchell N, Patel J, Roberts A, Saurigny D, Smith JE, Williamson R, Tak PP (2020) MRI of the joint and evaluation of the granulocyte\u2013macrophage colony-stimulating factor\u2013CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study. Lancet Rheumatol 2(11):e666\u2013e676. https:\/\/doi.org\/10.1016\/S2665-9913(20)30224-1","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"685_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12931-019-1010-5","volume":"20","author":"S Witt","year":"2019","unstructured":"Witt S, Krauss E, Barbero MAN, M\u00fcller V, Bonniaud P, Vancheri C, Wells AU, Vasakova M, Pesci A, Klepetko W, Seeger W, Crestani B, Leidl R, Holle R, Schwarzkopf L, Guenther A (2019) Psychometric properties and minimal important differences of SF-36 in idiopathic pulmonary fibrosis. Respir Res 20(1):47. https:\/\/doi.org\/10.1186\/s12931-019-1010-5","journal-title":"Respir Res"},{"issue":"5","key":"685_CR9","first-page":"664","volume":"33","author":"L Gossec","year":"2015","unstructured":"Gossec L, Steinberg G, Rouanet S, Combe B (2015) Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS study. Clin Exp Rheumatol 33(5):664\u2013670","journal-title":"Clin Exp Rheumatol"},{"issue":"14","key":"685_CR10","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1177\/0961203319886065","volume":"28","author":"M Jolly","year":"2019","unstructured":"Jolly M, Annapureddy N, Arnaud L, Devilliers H (2019) Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 trial. Lupus 28(14):1628\u20131639. https:\/\/doi.org\/10.1177\/0961203319886065","journal-title":"Lupus"},{"key":"685_CR11","volume-title":"User\u2019s manual for the SF-36v2 Health Survey","author":"ME Maruish","year":"2011","unstructured":"Maruish ME (2011) User\u2019s manual for the SF-36v2 Health Survey, 3rd edn. Quality Metric Incorporated: Lincoln, RI","edition":"3"},{"issue":"5","key":"685_CR12","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J (2005) Validation of the Functional Assessment of Chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 32(5):811\u2013819","journal-title":"J Rheumatol"},{"issue":"9","key":"685_CR13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/annrheumdis-2013-205079","volume":"74","author":"MM Ward","year":"2015","unstructured":"Ward MM, Guthrie LC, Alba MI (2015) Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Ann Rheum Dis 74(9):1691\u20131696. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205079","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"685_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11136-016-1390-7","volume":"25","author":"C Coon","year":"2016","unstructured":"Coon C (2016) Empirical telling the interpretation story: the case for strong anchors and multiple methods. Qual Life Res 25(1):1\u20132. https:\/\/doi.org\/10.1007\/s11136-016-1390-7","journal-title":"Qual Life Res"},{"issue":"2","key":"685_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102\u2013109. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.012","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"685_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1037\/\/0022-006x.59.1.12","volume":"59","author":"NS Jacobson","year":"1991","unstructured":"Jacobson NS, Truax P (1991) Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59(1):12\u201319. https:\/\/doi.org\/10.1037\/\/0022-006x.59.1.12","journal-title":"J Consult Clin Psychol"},{"issue":"3","key":"685_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02310555","volume":"16","author":"LJ Cronbach","year":"1951","unstructured":"Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16(3):297\u2013334. https:\/\/doi.org\/10.1007\/BF02310555","journal-title":"Psychometrika"},{"key":"685_CR18","volume-title":"Test theory: a unified treatment","author":"RP McDonald","year":"1999","unstructured":"McDonald RP (1999) Test theory: a unified treatment. Lawrence Erlbaum Associates, Mahwah, NJ"},{"issue":"1","key":"685_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11336-008-9101-0","volume":"74","author":"K Sijtsma","year":"2009","unstructured":"Sijtsma K (2009) On the use, the misuse, and the very limited usefulness of Cronbach\u2019s alpha. Psychometrika 74(1):107\u2013120. https:\/\/doi.org\/10.1007\/s11336-008-9101-0","journal-title":"Psychometrika"},{"issue":"5","key":"685_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1586\/14737167.4.5.581","volume":"4","author":"GR Norman","year":"2004","unstructured":"Norman GR, Sloan JA, Wyrwich KW (2004) The truly remarkable universality of half a standard deviation: confirmation through another look. Expert Rev Pharmacoecon Outcomes Res 4(5):581\u2013585. https:\/\/doi.org\/10.1586\/14737167.4.5.581","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"685_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.semarthrit.2020.02.011","volume":"50","author":"E van Mulligen","year":"2020","unstructured":"van Mulligen E, Weel A, Kuijper TM, Hazes JMW, van der Helm-van Mil AHM, de Jong PHP (2020) The impact of a disease flare during tapering of DMARDs on the lives of rheumatoid arthritis patients. Semin Arthritis Rheum 50(3):423\u2013431. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.02.011","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"685_CR22","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1136\/annrheumdis-2014-205302","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Kavanaugh A, Bao Y, Ganguli A, Mulani P (2015) Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Ann Rheum Dis 74(12):2165\u20132174. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205302","journal-title":"Ann Rheum Dis"},{"key":"685_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-022-03172-5","author":"JB Bjorner","year":"2022","unstructured":"Bjorner JB, Terluin B, Trigg A, Hu J, Brady KJS, Griffiths P (2022) Establishing thresholds for meaningful within-individual change using longitudinal item response theory. Qual Life Res 32(5):1267\u20131276. https:\/\/doi.org\/10.1007\/s11136-022-03172-5","journal-title":"Qual Life Res:Online Ahead of Print"},{"issue":"2 Suppl 1","key":"685_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","volume":"22","author":"DP Lubeck","year":"2004","unstructured":"Lubeck DP (2004) Patient-reported outcomes and their role iin the assessment of rheumatoid arthritis. PharmacoEconomics 22(2 Suppl 1):27\u201338. https:\/\/doi.org\/10.2165\/00019053-200422001-00004","journal-title":"PharmacoEconomics"},{"issue":"8","key":"685_CR25","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3899\/jrheum.110392","volume":"38","author":"V Strand","year":"2011","unstructured":"Strand V, Boers M, Idzerda L, Kirwan JR, Kvien TK, Tugwell PS, Dougados M (2011) It\u2019s good to feel better but it\u2019s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol 38(8):1720\u20131727. https:\/\/doi.org\/10.3899\/jrheum.110392","journal-title":"J Rheumatol"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00685-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T14:02:57Z","timestamp":1705932177000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00685-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["685"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00685-0","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"11 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this post-hoc secondary analysis of existing Phase 2 clinical trial data. However, patients provided consent for such secondary data analyses in the informed consent forms for the BAROQUE and RENAISSANCE clinical trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RR-B, MK, and JBB are employees of QualityMetric Inc, who received consulting fees for the conduct of this analysis but not for manuscript development. XL was an employee of QualityMetric Inc at the time of the study and is currently an employee of, and holds stocks\/shares in, Biogen. MGB and W-HC are employees of, and holds stocks\/shares in, GSK.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}